Table 4.
Results of NGS analyses of cytological and histological specimens from primary tumour and metastases from 16 patients with PM from pancreatic cancer
| Primary tumour | Histological biopsy prior to PIPAC* | PF before PIPAC | Histological peritoneal biopsy after PIPAC | PF after PIPAC | |
| Patient 1 | KRAS (p.Gly12Asp) | KRAS (p.Gly12Asp) | KRAS (p.Gly12Asp) | ND (PIPAC 3 and 4) | NA |
| Patient 2 |
KRAS (p.Gly12Val) TP53 (p.Cys275Tyr) |
KRAS (p.Gly12Val) | NA | KRAS (p.Gly12Val) (PIPAC 2 and 3) | NA |
| Patient 3 | ND | ND | NA | ND (PIPAC 2, 3, 4 and 5) |
ND (PIPAC 5) |
| Patient 4 | ND | KRAS (p.Gly12Val) | ND | KRAS (p.Gly12Val) (PIPAC2) | KRAS (p.Gly12Val) (PIPAC 2) |
| Patient 5 |
KRAS (p.Gly12Asp) SMAD4 (p.Arg135Ter) |
NA | NA |
KRAS (p.Gly12Asp) (PIPAC 2) SMAD4 (p.Arg135Ter) (PIPAC 2) ND (PIPAC 3) KRAS (p.Gly12Asp) (PIPAC 4) |
KRAS (p.Gly12Asp) (PIPAC 5) |
| Patient 6 | KRAS (Gly12Asp) | NA | NA | NA | NA |
| Patient 7 | KRAS (p.Gly12Val) | KRAS (p.Gly12Val) (lymph node) | NA | NA | NA |
| Patient 8 | NA | ND | KRAS (p.Gly12Asp) | NA | NA |
| Patient 9 | MET (p.Arg988Cys) | MET (p.Arg988Cys) (found in PM biopsy and lymph node biopsy) | NA | NA | NA |
| Patient 10 | ND |
KRAS (p.Gln61Arg) SMAD4 (p.Arg361Cys) |
KRAS (p.Gln61Arg) | KRAS (p.Gln61Arg) (PIPAC 2) | KRAS (p.Gln61Arg) (PIPAC 2) |
| Patient 11 | FGFR2 (p.Asn549Lys) | KRAS (p.Gly12Asp) | NA | NA | NA |
| Patient 12 |
KRAS
(p.Gly12Asp) |
NA | NA | NA | ND (PIPAC 3 and 4) |
| Patient 13 | KRAS (p.Gly12Val) | NA | NA | NA | NA |
| Patient 14 |
KRAS (p.Gly12Val) TP53 (p.Arg273His) |
NA | NA | NA | NA |
| Patient 15 | NA | KRAS (p.Gly12Arg) | KRAS (p.Gly12Arg) | KRAS (p.Gly12Arg) | KRAS (p.Gly12Arg) (PIPAC 2) |
| Patient 16 | NA | KRAS (p.Gly12Ala) | ND | ND | ND (PIPAC 2) |
*NGS of histological biopsy from peritoneum, unless something else is stated.
NA, not available; ND, not detected; NGS, next-generation sequencing; PF, peritoneal fluid; PM, peritoneal metastasis.